Kalnik Matthew W. 4
4 · NABI BIOPHARMACEUTICALS · Filed Apr 15, 2010
Insider Transaction Report
Form 4
Kalnik Matthew W.
SVP Strategic Plan. & Bus. Ops
Transactions
- Sale
Common Stock
2010-04-13$5.78/sh−2,250$13,005→ 47,350.104 total
Footnotes (1)
- [F1]The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.